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A B S T R A C T
Purpose
Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for
estrogen receptor (ER) –positive breast cancer. To study this treatment option, responses to three
AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase
III investigations.
Patients and Methods
Three hundred seventy-seven postmenopausal women with clinical stage II to III ER-positive
(Allred score 6-8) breast cancer were randomly assigned to receive neoadjuvant exemestane,
letrozole, or anastrozole. The primary end point was clinical response. Secondary end points
included BCS, Ki67 proliferation marker changes, the Preoperative Endocrine Prognostic Index
(PEPI), and PAM50-based intrinsic subtype analysis.
Results
On the basis of clinical response rates, letrozole and anastrozole were selected for further
investigation; however, no other differences in surgical outcome, PEPI score, or Ki67 suppression
were detected. The BCS rate for mastectomy-only patients at presentation was 51%. PAM50
analysis identified AI-unresponsive nonluminal subtypes (human epidermal growth factor receptor
2 enriched or basal-like) in 3.3% of patients. Clinical response and surgical outcomes were similar
in luminal A (LumA) versus luminal B tumors; however, a PEPI of 0 (best prognostic group) was
highest in the LumA subset (27.1% v 10.7%; P  .004).
Conclusion
Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demon-
strated that the three agents tested are biologically equivalent and therefore likely to have similar
adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics
after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with  5%
increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be
detected by post-treatment profiling.
J Clin Oncol 29:2342-2349. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Neoadjuvant aromatase inhibitor (AI) therapy is a
low-toxicity approach that improves the breast con-
servation rate for postmenopausal women with clin-
ical stage 2 or 3 estrogen receptor (ER) –positive
breast cancer.1 However, chemotherapy is still
widely used in this setting despite promising small
studies showing little advantage over an endocrine
approach.2 The lack of a practice standard reflects
the absence of a phase III trial definitively comparing
neoadjuvant aromatase inhibition with neoadjuvant
chemotherapy. Unfortunately, the design of such a
study is not straightforward, because pathologic
complete response (CR) rates are low in ER-positive
disease regardless of treatment modality, suggesting
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other primary end points must be considered.3,4 However, the clinical
response rate (cRR) traditionally used in neoadjuvant endocrine stud-
ies is not verifiable, and radiologic response end points are not stan-
dardized.5 Surgical outcome improvement is a logical primary end
point, but surgical decisions are subject to bias when blinded
treatments are not possible. The choice between anastrozole, letro-
zole, and exemestane is also an important consideration. The re-
sults of large randomized trials comparing these agents as adjuvant
therapy are underway (eg, NCT00438529, NCT00248170, and
NCT00541086). AIs have differences with respect to estradiol and
estrone sulfate suppression, which could translate into differences
in clinical responsiveness.6
An alternative to conventional primary end points for neoadju-
vant endocrine therapy trials is the Ki67 proliferation biomarker.7-10
Tumor Ki67 levels determined after initiation of neoadjuvant endo-
crine treatment are markedly more prognostic than baseline analy-
sis,11 and Ki67 data have been integrated into a post-treatment model
that also includes pathologic stage and ER levels, referred to as the
Preoperative Endocrine Prognostic Index (PEPI). Patients with
pathologically node-negative T1 or T2 disease with a fully suppressed
Ki67 level ( 2.7% or 1% on a natural log scale) and persistent ER
expression after completion of neoadjuvant endocrine therapy (PEPI
of 0) were found to have such a low risk of relapse that adjuvant
chemotherapy after neoadjuvant endocrine therapy may not be nec-
essary.12 Prognostic biomarker analysis based on tumor samples taken
after treatment initiation is distinct from recent genomic approaches
based on pretreatment sample analysis.13-15 An integration of pre- and
post-treatment biomarkers, could therefore improve prognostic algo-
rithms and help identify patients for whom neoadjuvant endocrine
therapy is appropriate, because adjuvant chemotherapy is unneces-
sary treatment.
To investigate these issues, the ACOSOG (American College of
Surgeons Oncology Group) Z1031 trial, a randomized phase II study
designed to select AIs for future studies, was conducted. The trial
design prospectively incorporated an analysis of the PEPI approach
(based on post-treatment sample analysis)12 and the PAM50-based
intrinsic subtype model (based on pretreatment sample analysis)15 to
compare these distinct approaches with prognostication for patients
with ER-positive disease.
PATIENTS AND METHODS
Study Design
The Z1031 study is a phase II screening trial designed to determine which
AIs (exemestane, letrozole, or anastrozole, one, two, or any of the three) should
be chosen for future investigation. The study was supported by the Clinical
Trials Support Unit and approved by the institutional review boards of all
participating institutions; all patients provided signed informed consent. Eli-
gible patients were menopausal (verified by bilateral surgical oophorectomy,
no spontaneous menses for more than 1 year, or no menses for less than 1 year
but follicle-stimulating hormone and estradiol levels in postmenopausal
range), with clinical stage T2-T4c, N0-3, M0 breast cancer. Additional criteria
were palpable lesion measuring more than 2 cm in at least one dimension;
ER-positive disease with an Allred score of 6 to 8,16 Eastern Cooperative
Oncology Group performance status of 0 to 2, and a mammogram or ultra-
sound taken within 42 days before registration. Exclusion criteria included
prior treatment for invasive breast cancer, hormone replacement therapy,
megestrol acetate or raloxifene within 1 week before registration, inflamma-
tory breast cancer, and other malignancy less than 5 years before registration
(except for nonmelanomatous skin cancer, lobular carcinoma in situ of the
breast, contralateral ductal carcinoma in situ not treated with endocrine ther-
apy, and carcinoma in situ of the cervix). At baseline, patients were categorized
as marginal candidate for breast conservation, only eligible for mastectomy, or
inoperable by standard mastectomy.
Treatment Administration and Evaluation
Eligible patients were treated with exemestane 25 mg daily, letrozole 2.5
mg daily, or anastrozole 1 mg daily for 16 to 18 weeks before surgery. Treat-
ment was discontinued if disease progression was confirmed by ultrasound or
mammogram, if severe toxicity (National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 3.0, grades 3 to 5) was reported as
probably or definitely related to treatment, or if the patient withdrew consent.
Within 14 days of registration, patients underwent a complete physical exam-
ination; assessment of Eastern Cooperative Oncology Group performance
status; and tumor assessment by tape, ruler, or caliper. Patients were randomly
assigned to treatment using a dynamic allocation procedure that balanced the
marginal distributions of clinical tumor stage (T2 v T3 v T4) between treat-
ment arms. Every 4 weeks, patients underwent a physical examination, toxicity
assessment, and tumor assessment using WHO criteria. If tumor progression
was suspected, ultrasound or mammogram was required for confirmation.
Blood and biopsy specimens for correlative studies were collected at baseline
and surgery or on discontinuation of endocrine therapy.
Statistical Considerations
The primary end point was the cRR (CRs and partial responses [PRs] as
defined by WHO criteria) after 16 to18 weeks of treatment. The last bidimen-
sional clinical measurements, taken between 80 and 140 days after registration,
were used to determine clinical tumor response. The trial was designed to
select a treatment or treatments for further study so that there would be a 90%
probability that the subset selected would include the AI with the truly highest
cRR. Simulation studies with a sample size of 125 patients per arm generated a
decision rule whereby the AI with the highest number of clinical responses
(best agent) and any other agent(s) that had at most 12 fewer responses than
the best agent would be included in the selected subset for further study. For
example, the likelihood of selecting a single agent with the truly best response
rate was 0.96 if the cRRs were 50%, 60%, and 80%, respectively. The likelihood
of selecting two agents, if the cRRs for three agents were 50%, 70%, and 70%,
respectively, was 0.90. An interval estimate for the true cRR for a given treat-
ment was constructed using a 95% binomial CI for a single proportion.
Pairwise differences between treatments in terms of true cRR were examined
using 95% z-CIs for the true difference between independent proportions.
Univariate logistic regression modeling was used to assess whether likelihood
of a clinical response differed with respect to the baseline patient characteris-
tics: histologic grade, cT stage, cN0, local laboratory, Allred score, or surgical
status. Because none were found (likelihood ratio testPvalues .05), assessing
whether likelihood of clinical response differed with respect to treatment
adjusting for significant baseline factors was abandoned. Among the subgroup
of patients with PAM50 data, stratified logistic regression modeling was used
to assess whether the likelihood of clinical response, breast-conserving surgery
(BCS), or PEPI of 0 differed with respect to disease characteristics. The stratum
was assigned treatment. For continuous and ordinal factors, Wilcoxon rank
sum tests or Kruskal-Wallis tests were used to examine differences between
intrinsic subtypes or treatment arms. Wilcoxon signed rank tests were used to
examine pre- and post-treatment changes.
Biomarker Analysis
Tissue samples at baseline and surgery were submitted for PAM50-based
intrinsic subtype assignment, ER Allred score, and Ki67 proliferation marker.
Baseline tumor RNA was extracted from biopsies with at least 50% tumor; data
were generated on an Agilent microarray platform (Santa Clara, CA) and
analyzed using the PAM50 algorithm.15 Array data normalization approaches
and biomarker methodologies are provided in the Data Supplement. PAM50-
based hierarchical clustering of Z1031 samples and subtype controls are pro-
vided in Appendix Figure A1, online only.
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RESULTS
Patient Cohort
From January 4, 2006, to January 10, 2009, 377 postmenopausal
women with clinical stage II or III ER-positive breast cancer were
enrolled. One patient randomly assigned to receive letrozole and two
patients randomly assigned to receive anastrozole withdrew consent
before receiving any study treatment and were excluded. The remain-
ing 374 patients compose the analysis cohort (Fig 1). Patient and
disease characteristics are presented by treatment arm in Appendix
Table A1, online only. A smaller percentage of patients randomly
assigned to receive letrozole had cN0 disease, and a larger percentage
of patients with an Allred score of 6 (by local testing) were randomly
assigned to receive anastrozole. There was no difference in treatment
duration between treatment arms (Appendix Table A2, online only).
Treatment Tolerability
No severe toxicity was reported by more than 5% of the patients.
The most common grade 2 toxicity was hot flashes/flushes (Appendix
Table A3, online only).
Clinical Response
Of the 124 patients receiving exemestane, 27 experienced CRs, 51
experienced PRs, 28 achieved stable disease (SD), and eight experi-
enced progressive disease (PD)/sec primaries; baseline and/or final
bidimensional measurements were not available (NA) for 10 patients
because of treatment discontinuation (n 5) or measurement failure
(n 5). Therefore, the cRR was 62.9% (95% CI, 53.8% to 71.4%). Of
127 patients receiving letrozole, 27 experienced CRs, 68 experienced
PRs, 20 achieved SD, and six experienced PD; data for six were NA
because of treatment discontinuation (n  3) or measurement failure
(n3). The cRR was therefore 74.8% (95% CI, 66.3% to 82.1%). Of 123
patients receiving anastrozole, 22 experienced CRs, 63 experienced PRs,
20 achieved SD, and nine experienced PD; data for nine were NA because
of treatment discontinuation (n  2) and failure to measure (n  7).
Therefore, the cRR was 69.1% (95% CI, 60.1% to 77.1%). Letrozole
exhibited the highest cRR, and the difference in the number of responses
between letrozole and anastrozole was fewer than 12; thus, these two
agents comprise the subset for further consideration (Table 1).
Table 1. Clinical Response Using WHO Criteria Based on ITT Population
Response
Exemestane
(n  124)
Letrozole
(n  127)
Anastrozole
(n  123)
No. % No. % No. %
Clinical response at week 16
(WHO criteria with caliper
measurements)
Complete response 27 21.8 27 21.3 22 17.9
Partial response 51 41.1 68 53.5 63 51.2
No change 28 22.6 20 15.7 20 16.3
Disease progression 8 6.5 6 4.7 9 7.3
Off treatment because of
toxicity/refusal 5 4.0 3 2.4 2 1.6
Measurements not done 5 4.0 3 2.4 7 5.7
ITT clinical response rate, % 62.9 74.8 69.1
Range 53.8-71.4 66.3-82.1 60.1-77.1
95% CI, % (difference in
clinical response rates)
Letrozole and exemestane 0.5 to 23.3
Anastrozole and exemestane 5.6 to 18.0
Letrozole and anastrozole 5.4 to 16.8
Abbreviation: ITT, intent to treat.
Exemestane
(n = 124)
Surgery
performed
after
completion of
AI
(n = 115)
Surgery
performed
after
completion of
AI
(n = 120)
Surgery
performed
after
completion of
AI
(n = 117)
Surgery not performed
   Refusal
   Progressive disease
Alternative therapy prior 
   to surgery
Unable to determine baseline
   intrinsic subtype (n = 37) or
      whether PEPI was zero (n = 4) 
         or both (n = 7)
Missing surgery Ki67 (n = 1) or
   Allred score (n = 7) or both (n = 15)
Unable to determine baseline
   intrinsic subtype (n = 30) or
      whether PEPI was zero (n = 7) 
         or both (n = 6)
Missing surgery Ki67 (n = 0) or
   Allred score (n = 2) or both (n = 15)
Unable to determine baseline
   intrinsic subtype (n = 35) or
      whether PEPI was zero (n = 5) 
         or both (n = 8)
Missing surgery Ki67 (n = 0) or
   Allred score (n = 4) or both (n = 20)
(n = 4)
(n = 2)
(n = 3)
Surgery not performed
   Refusal
   Progressive disease
Alternative therapy prior 
   to surgery
(n = 3)
(n = 1)
(n = 2)
Surgery not performed
   Refusal
   Concurrent medical
      condition
(n = 4)
 
(n = 3)
Ineligible
   Mammogram outside 42-day window 
      or not done
   Metastatic disease present
   Baseline caliper measurements not done
Missing baseline Ki67 (n = 0) or 
   Allred score (n = 1) or both (n = 17)
(n = 6)
(n = 1)
(n = 2)
Letrozole
(n = 128)
Ineligible
   Mammogram outside 42-day window 
      or not done
   Baseline ultrasound not done for 
      cN1 disease
Withdrew consent prior to start of treatment
Missing baseline Ki67 (n = 2) or 
   Allred score (n = 1) or both (n = 28)
(n = 6)
(n = 2)
(n = 1)
Anastrozole
(n = 125)
Ineligible
   Mammogram outside 42-day window 
      or not done
   Baseline caliper measurements not done
Withdrew consent prior to start of treatment
Missing baseline Ki67 (n = 1) or 
   Allred score (n = 0) or both (n = 20)
(n = 5)
(n = 1)
(n = 2)
Fig 1. CONSORT diagram. AI, aromatase inhibitor; PEPI, Preoperative Endocrine Prognostic Index.
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Surgical Outcomes
Seventeen patients did not undergo surgery because of patient
refusal (n 12), PD (n 3), or concurrent medical conditions (n 2).
Another five patients received alternative systemic therapy before sur-
gery. The remaining 352 patients form the surgical cohort (Fig 1).
Fifty-one percent who were designated candidates for mastectomy
only before therapy received BCS, and 83% of those considered mar-
ginal for BCS at baseline experienced successful breast conservation
(Table 2). Pathologic findings were similar between treatment arms
(Appendix Table A4, online only).
Analysis of Ki67 and PEPI by Treatment Arm
No differences were found between treatments with respect to
baseline Ki67 levels (Kruskal-Wallis test P .85) or changes in Ki67
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Fig 2. Distribution of biomarkers by treatment assignments and intrinsic subtypes. (A) Geometric mean percentage suppression of Ki67 from baseline by treatment
arm to graphically summarize the overall treatment effect on each arm (Data Supplement). There was no significant difference in Ki67 suppression between treatment
arms (Kruskal-Wallis P  .45, adjusted for three-way comparison). (B) Box plots of baseline and surgery Ki67 values in luminal A (LumA), luminal B (LumB), and human
epidermal growth factor receptor 2 (HER2) –enriched breast cancer subtypes (P values listed in Table 3). (C) Box plots of baseline and surgery estrogen receptor Allred
values in LumA, LumB, and HER2-enriched breast cancer subtypes (P values listed in Table 3). (D, E, F) Arrow plots showing individual paired Ki67 values in (D) LumA,
(E) LumB, and (F) HER2-enriched breast cancer subtypes. Red arrows highlight patients with paradoxical increase in Ki67 values.
Table 2. Surgical Procedures Performed After Neoadjuvant AI Therapy by Treatment Arm and Baseline Surgical Feasibility
Type of Surgical Candidate
Before AI Therapy
Most Extensive Surgery
Performed
Treatment Arm
Total
Exemestane
(n  115)
Letrozole
(n  120)
Anastrozole
(n  117)
No. % No. % No. % No. %
Marginal for breast conservation
(n  189) Breast conserved 52 45.2 48 40.0 57 48.7 157 83.1
Mastectomy 9 7.8 14 11.8 9 7.7 32 16.9
Candidate for mastectomy only
(n  159) Breast conserved 25 21.7 24 20.0 32 27.4 81 50.9
Mastectomy 27 23.5 33 27.5 18 15.4 78 49.1
Inoperable by standard mastectomy
(n  4) Breast conserved 1 0.9 1 0.8 1 0.9 3 75.0
Mastectomy 1 0.9 — — 1 25.0
Abbreviation: AI, aromatase inhibitor.
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after treatment (Kruskal-Wallis test P .45). Following the approach
of Dowsett et al,7 the geometric mean percentage change in Ki67 for
each treatment was determined: anastrozole78% (standard error of
the mean [SEM], 4%), exemestane81.2% (SEM, 3.5%), and letro-
zole 87.1% (SEM, 2.8%; Fig 2A). Within the limits of the sample
size, the three treatments therefore had biologically equivalent effects.
There were 315 patients in whom it could be determined whether the
PEPI score was 0 or not (reasons for lack of data in the remaining patients
included inadequate sample provision and absent axillary staging). No
differenceswerefoundbetweenthetreatmentswithrespecttothepropor-
tion of patients with PEPI of 0 (P  .9; anastrozole, 17.3%; letrozole,
15.9%; exemestane, 15.6%; Appendix Table A5, online only).
PAM50 Intrinsic Subtype, Ki67 Proliferation Index, and
ER Allred Scores
Of the 315 patients with PEPI data, there were 102 patients for
whom the PAM50 intrinsic subtype could not obtained, principally
because of inadequate frozen tumor tissue. The assignments were
luminal A (LumA, 85 patients), luminal B (LumB, 119 patients),
normal (two patients), human epidermal growth factor receptor 2
(HER2) enriched (six patients), and basal-like (one patient). The
normal-like samples were not considered further, because these spec-
imens may not have been sufficiently tumor rich to assign a breast
cancer subtype.15 Both the baseline Ki67 values and surgical specimen
Ki67 values were significantly higher in LumB versus LumA breast
cancer (Fig 2B; Table 3). The single basal-like patient demonstrated
high pre- and post-treatment Ki67 values consistent with endocrine
therapy resistance (38% and 26.8%, respectively) as well as low ER
Allred scores (3 and 0, respectively). All five HER2-enriched patients
had persistently high surgical Ki67 levels ( 20%), consistent with
high-level estrogen-independent growth (Table 3; Fig 2B, 2F). ER
decreased after treatment in both LumA (P  .001) and LumB pa-
tients (P .001; Table 3; Fig 2C). Paradoxical increases in Ki67 in the
surgical sample compared with baseline greater than 5% were seen in
Table 3. ER and Ki67 Immunohistochemistry Biomarker Results in LumA Versus LumB Versus HER2-Enriched Breast Cancers Assigned by Microarray Profiling
and Application of PAM50 Algorithm
Result LumA LumB HER2 Enriched P 
Baseline Ki67 LumA v LumB:  .001
No. 89 119 6
Median, % 7.7 29.0 59.4
Range, % 0-52.1 1.2-80.5 37.8-90.5
 10%, % 57.3 6.7 0 LumA v HER2 enriched: .001
 10%, % 42.7 93.3 100 LumB v HER2 enriched: .0032
Post-AI Ki67
No. 82 114 5
Median, % 2.6 4.1 35.7 LumA v LumB: .001
Range, % 0-81.9 0-47.1 21.6-88.2
 1%, % 32.9 16.7 0 LumA v HER2 enriched:  .001
 1%, % 67.1 83.3 100 LumB v HER2 enriched: .0012
Change in Ki67 (after  before)
No. 73 104 5
Median, % 4.6 20.4 8.0 LumA v LumB:  .001
Range, % 51.5-81.4 72.8-30.9 29.0-2.27
Wilcoxon signed rank P  .001  .001 NS LumA v HER2 enriched: NS
 5% paradoxical increase, % 12.3 5.8 0 LumB v HER2 enriched: NS
Baseline Allred scores
No. 90 118 6
Median 7.0 7.0 4.5 LumA v LumB: NS
Range 3-8 0-8 0-8
 5, % 17.8 12.7 66.7 LumA v HER2 enriched: NS
 6, % 82.2 87.3 33.3 LumB v HER2 enriched: NS
Post Allred scores
No. 80 112 5
Median 6.0 6 3 LumA v LumB: NS
Range 0-8 0-8 0-7
 5, % 35.0 38.4 80.0 LumA v HER2 enriched: NS
 6, % 65.0 61.6 20.0 LumB v HER2 enriched: NS
Change in Allred Scores (before  after)
No. 73 101 5 LumA v LumB: NS
Median 1 1 0 LumA v HER2 enriched: NS
Range 7-4 8-7 4-2
Wilcoxon signed rank P .0012  .001 NS LumA v HER2 enriched: NS
NOTE. Nonparametric testing was used throughout to assign statistical significance because of non-normal distribution of Ki67 data.
Abbreviations: ER, estrogen receptor; LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; AI, aromatase inhibitor; NS,
not significant.
To account for multiple testing, P  .01 was considered significant for within-group comparisons of Ki67 and Allred score, and P  .0055 was considered
significant for between-group comparisons of Ki67 and Allred score.
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12.3% of LumA patients, 5.8% of LumB patients, and none of the
HER2-enriched patients. Paradoxical Ki67 increases are highlighted
with red arrow plots in Figures 2D to 2F for LumA, LumB, and HER2
enriched, respectively.
Clinical Response, Surgical Outcomes, and PEPI
Scores in LumA and LumB Subtypes
No differences between the likelihood of BCS or clinical response
were found between LumA and LumB tumors (Appendix Table A6,
online only). However, 27.1% of patients with tumors considered
LumA were assigned PEPI-0 status at surgery in contrast with 10.7%
of patients assigned LumB status (P  .004; Appendix Table A7,
online only). In univariable analysis, a baseline Ki-67 level less than or
equal to 10% (P .018) and LumA subtype status (P .004) were
significantly associated with an increased likelihood of a PEPI of 0. In
multivariate analyses, LumA subtype assignment was the dominant
factor predicting the likelihood of PEPI-0 status (Table 4).
DISCUSSION
The results from this study confirm earlier trial results demonstrating
that marked improvements in surgical outcomes are achievable with
neoadjuvant aromatase inhibitor therapy. This low toxicity approach
is therefore a reasonable standard of care for selected patients with
ER-rich HER2-negative breast cancer who desire breast conservation
despite clinical stage 2 or 3 disease.17,18 Limiting treatment to patients
with tumor Allred scores of 6 or higher in Z1031 was based on of the
findings of the letrozole P024 trial19 and is a reasonable guideline for
clinical practice. The overall breast conservation rate of 68% in Z1031
compares well with the surgical outcome improvements achieved
with doxorubicin and cyclophosphamide in the NSABP (National
Surgical Adjuvant Breast and Bowel Project) B18 trial.20
The phase II statistical design selected letrozole or anastrozole for
further study. However, no statistically significant differences with
respect to Ki67 changes or PEPI values were detected. Thus, exemes-
tane should not be necessarily excluded from investigation in the
neoadjuvant setting, particularly if drug interactions or other factors
preclude the use of nonsteroidal AIs. Importantly, the Ki67-based data
demonstrate that the biologic activities of the three AIs studied are
closely equivalent, therefore predicting similar activity as adjuvant
therapies. In the case of exemestane and anastrozole, this has recently
been shown to be the case. The NCIC (National Cancer Institute of
Canada) MA27 trial showed no statistical differences in any trial
end point in 7,576 patients who were randomly assigned to treat-
ment with one or the other of these two agents.21 It is therefore
becoming increasingly illogical to embark on phase III adjuvant
endocrine therapy studies on the basis of a superiority hypothesis
without proof of greater biologic effectiveness of the experimental
agent generated by a neoadjuvant Ki67 study. Although the neo-
adjuvant paradigm has been widely promoted for predicting the
activity of adjuvant chemotherapy regimens,22,23 our findings
demonstrate that the case for endocrine agents also holds as long as
conclusions are based on Ki67 suppression rather than pCR. The
approximate 80% geometric mean Ki67 suppression observed with
anastrozole in the IMPACT (Immediate Preoperative Anastrozole,
Tamoxifen, or Combined with Tamoxifen) trial7 is similar to our
Table 4. Results of Stratified Logistic Regression Modeling of Baseline Factors to Potential to Predict PEPI-0 Status
Factor No. PEPI Score of 0 (%)
Wald Test
P
Univariate Multivariate
OR 95% CI OR 95% CI
Clinical T size
T2 150 18.7 .433 1.41 0.60 to 3.30
T3/T4a-c 56 14.3
Clinical nodal status
Positive 143 20.3 .144 1.94 0.80 to 4.70
Negative 63 11.1
HER2 (local)
Negative 184 17.4 .575 1.54 0.34 to 7.05
Positive 17 11.8
Baseline Ki67, %
 10 50 28.0 .018 2.61 1.18 to 5.78
 10 135 12.6
Baseline histologic grade
1 35 20.0 .732 1.18 0.47 to 2.97
2-3 170 17.1
Baseline ER score, Allred (central testing)
6-8 159 16.4 .924 1.06 0.34 to 3.32
 5 26 15.4
Intrinsic subtype
LumA 85 27.1 .004 2.99 1.42 to 6.31 2.99 1.42 to 6.31
LumB 121 10.7
NOTE. Aromatase inhibitor treatment was stratification factor. Six tumors were assigned nonluminal intrinsic subtypes: five HER2 enriched and one basal-like. None
of these patients achieved PEPI-0 status and were therefore not included in analysis, which dichotomized tumors as either LumA or LumB according to PAM50
intrinsic subtype. This analysis included patients who could be assigned to non–PEPI-0 group, even though some elements of analysis were not available.
Abbreviations: PEPI, Preoperative Endocrine Prognostic Index; OR, odds ratio; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; LumA,
luminal A; LumB, luminal B.
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observations in Z1031 (Fig 2A), underscoring the consistency of
the Ki67 approach.
In terms of the identification of suitable patient populations for
neoadjuvant endocrine therapy, PAM50 intrinsic subtype analysis
seems useful for excluding uncommon nonluminal intrinsically en-
docrine therapy–resistant tumors present, despite trial eligibility
requiring strong ER expression (3.3% were HER2 enriched or basal-
like). Both LumA and LumB tumors were highly endocrine-therapy
responsive at the clinical and biomarker level; however, LumB tumors
had significantly higher post-treatment Ki67 levels, consistent with the
worse prognosis associated with this subtype.14,15 Therefore, patients
with LumA breast cancer may be particularly suitable for neoadjuvant
endocrine therapy, because approximately one quarter of these pa-
tients have a PEPI of 0, implying that a prognosis with adjuvant
endocrine therapy may be sufficient without adjuvant chemotherapy
treatment.12 In the absence of a PAM50 result, a baseline Ki67 level of
10% or less was significant in univariable analysis for predicting
PEPI-0 status and could also be used to identify patients at baseline
suitable for neoadjuvant endocrine therapy. However, Ki67 pro-
duced a smaller LumA-like population (27%) than the gene ex-
pression profiling– based LumA definition (41%). Practically
speaking, the Ki67 assay provides a backup approach when tissue
sampling is inadequate for gene expression profiling, and the two
tests can be considered complementary.
Paradoxical Ki67 increases after neoadjuvant endocrine therapy
have been observed in other studies.7,8 In Z1031, paradoxical rises
were observed even when both the baseline Ki67 was low and the
subtype assignment was LumA (Fig 2D), suggesting the increase was
not simply the result of erroneously low baseline Ki67 values. A pos-
sible explanation is that some tumors assigned good-prognosis status
harbor occult treatment-resistant cellular populations that become
evident after neoadjuvant endocrine treatment. Decreased levels of ER
after treatment, as seen in this study as well as in previously published
work,8,12 also likely reflect the biology of endocrine resistance. In
general, tumor heterogeneity is a likely explanation for why baseline
tests, whether simple Ki67 or complex gene expression analysis, fail to
identify ultra–low-risk populations in the setting of stages 2 and 3
disease.14,24 Neoadjuvant endocrine therapy and repeated tumor sam-
pling is a practical approach to address the heterogeneity issue.
Conclusions regarding the routine use of neoadjuvant endocrine
therapy from this trial will be strengthened by relapse-free survival
data. The study design requires that each patient is observed for 10
years. Of particular interest will be the prognostic integrity of the PEPI
score, the PAM50 subtype assignments, and the in-breast recurrence
rate for patients who experience neoadjuvant AI-assisted breast con-
servation. The development of a reliable and controlled clinical testing
environment for both the PAM50 test as well as the Ki67 assay is also
critical for further progress, particularly given the difficulties of meth-
odologically reproducing data with gene expression signatures in the
research setting, even when the genomic algorithm is fixed.25,26
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